MARKET

ABCL

ABCL

Abcellera Biologics Inc.
NASDAQ
3.900
-0.070
-1.76%
Closed 19:14 04/24 EDT
OPEN
4.010
PREV CLOSE
3.970
HIGH
4.250
LOW
3.890
VOLUME
1.60M
TURNOVER
0
52 WEEK HIGH
8.05
52 WEEK LOW
3.790
MARKET CAP
1.14B
P/E (TTM)
-7.7029
1D
5D
1M
3M
1Y
5Y
In the wake of AbCellera Biologics Inc.'s (NASDAQ:ABCL) latest US$91m market cap drop, institutional owners may be forced to take severe actions
AbCellera Biologics Inc. Has a market cap of US$1.1b. The company has a large number of institutional investors in its share price. The top 8 shareholders of AbCellera biologics own 27% of the company. This suggests the company is sensitive to its own shareholders. The CEO of Abcellera Biologistics is the largest shareholder. It's worth looking at the company's ownership of shares to see if insiders are aligned with shareholders. AbCellERA Biologic's market cap has fallen 46% in the last year.
Simply Wall St · 3d ago
Weekly Report: what happened at ABCL last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at ABCL last week (0408-0412)?
Weekly Report · 04/15 09:13
AbCellera Presents Data On T-Cell Engagers Against Four Tumor Targets At AACR 2024
AbCellera announces new data on its T-cell engager programs at the American Association for Cancer Research. AbCellera is well-positioned to advance TCEs as a drug class by widening the therapeutic window and broadening the accessible target space. CD3-binding antibodies consistently generate T- cell engagers with potent tumor-cell killing and low cytokine release across multiple tumor targets.
Benzinga · 04/08 16:06
Weekly Report: what happened at ABCL last week (0401-0405)?
Weekly Report · 04/08 09:14
Weekly Report: what happened at ABCL last week (0325-0329)?
Weekly Report · 04/01 09:14
Weekly Report: what happened at ABCL last week (0318-0322)?
Weekly Report · 03/25 09:14
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
AbCellera will present at the Bloom Burton Healthcare Conference on April 16, 2024. A live audio webcast of the presentation will be available on abcellera's investor relations website. AbCellera discovers and develops antibody medicines for indications across therapeutic areas. The company's executives will present.
Barchart · 03/19 15:05
More
About ABCL
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.

Webull offers AbCellera Biologics Inc stock information, including NASDAQ: ABCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABCL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABCL stock methods without spending real money on the virtual paper trading platform.